Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

US9040566B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Jürgen Klar · Wuppertal, DE
• Georges Von Degenfeld · Leverkusen, DE
• Hans-Georg Lerchen · Leverkusen, DE
• Barbara Albrecht-Küpper · Uerdingen, DE
• Andreas Knorr · Erkrath, DE
• Peter Sandner · Wuppertal, DE
• Daniel Meibom · Leverkusen, DE

Key dates

• Filing date: Aug 29, 2011
• Grant date: May 26, 2015
• Expiry date: Aug 29, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the use of selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the treatment and/or prophylaxis of glaucoma and ocular hypertension as well as the their use for the production of a medicament for the treatment and/or prophylaxis of glaucoma and ocular hypertension.